Menssana Research, Inc is touting results from a trial testing its Breathscanner for diagnosing patients with active pulmonary tuberculosis. Menssana has developed technology that may bring breath testing for a variety of conditions, including the already FDA approved breath test for heart transplant rejection.
Some details about the technology from Menssana:
The Mycobacteria that cause pulmonary TB generate a very distinctive pattern of volatile organic compounds (VOCs) when grown in the laboratory. If these VOCs could also be detected in the breath of infected patients, it might provide a new method for detecting active infection with pulmonary TB. Read more »
*This blog post was originally published at Medgadget*